Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with significant unmet medical needs. The company has introduced LUPKYNIS® (voclosporin), the first FDA-approved oral treatment for adult lupus nephritis, and is advancing AUR200, a dual inhibitor targeting BAFF and APRIL for broader autoimmune disease treatments. Aurinia's focus on innovative drug development positions it as a leader in addressing complex immunological conditions.
We are a dedicated team of experts committed to changing the trajectory of autoimmune diseases with unmet medical needs. The Immunology Sales Specialist is responsible for calling on practicing physicians, hospitals, clinics, and other health-related organizations within the assigned territory to provide current and comprehensive clinical knowledge of Aurinia's product and effectively communicate its clinical and economic benefits.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with significant unmet medical needs. The company has introduced LUPKYNIS® (voclosporin), the first FDA-approved oral treatment for adult lupus nephritis, and is advancing AUR200, a dual inhibitor targeting BAFF and APRIL for broader autoimmune disease treatments. Aurinia's focus on innovative drug development positions it as a leader in addressing complex immunological conditions.
Aurinia Pharmaceuticals Inc.